NCT06673498 Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
| NCT ID | NCT06673498 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Anhui Provincial Hospital |
| Condition | Thrombocytopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-11-10 |
| Primary Completion | 2025-11-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.
Eligibility Criteria
Inclusion Criteria: * Ability to understand the study and willingness to comply with all study procedures by voluntarily signing an informed consent form prior to screening. * Male or female, 18 years of age or older at the time of signing the informed consent form. * Patients with chronic liver disease. * Baseline platelet count ≤ 35 x 109/L prior to enrolment on day 1. * Proposed elective invasive surgery that meets the following conditions: - Platelet transfusion may be required - Expected to be performed between days 9 and 15 after enrolment - Excludes extremely high-risk surgical operations such as open abdomen, open chest, open skull, and direct cardiac surgery. * Eastern Collaborative Oncology Group (ECOG) Physical Status (PS) score of 0 or 1. * According to the researcher, it will be able to fulfil the requirements of this study. * Male patients who are infertile or who agree to use adequate contraception (including the use of condoms containing spermicides) from the start of s